Overview
Erythrodermic mycosis fungoides is a severe, disseminated form of cutaneous T-cell lymphoma characterized by widespread skin redness, scaling, and significant systemic involvement 4. It represents an advanced stage of mycosis fungoides, often presenting with erythroderma as a prominent feature.Diagnosis
Clinical Presentation: Widespread erythema, scaling, and potential systemic symptoms including fever and malaise 4.
Histopathology: Biopsy showing atypical lymphocytes in the dermis consistent with mycosis fungoides 4.
Immunophenotyping: Immunohistochemical analysis identifying CD4+ or CD8+ T-cell markers 4.
Exclusion of Other Causes: Ruling out other causes of erythroderma such as infections, drug reactions, and other dermatoses through comprehensive evaluation 23.Management
Supportive Care: Intensive hydration, temperature regulation, and management of systemic complications 2.
Topical Treatments: Emollients and topical corticosteroids to manage pruritus and skin barrier function 2.
Systemic Therapy: Corticosteroids for acute management, often followed by chemotherapy (e.g., nitrogen mustard) or targeted therapies (e.g., retinoids) 4.
Immunosuppressive Agents: Mycophenolate mofetil or cyclosporine may be considered in refractory cases 4.Special Populations
Pediatrics: Erythroderma in children often has varied etiologies including infections, atopic dermatitis, and genodermatoses; management is primarily supportive 2.
Comorbidities: Special attention to systemic involvement and potential life-threatening complications, requiring multidisciplinary care 4.Key Recommendations
Biopsy for Diagnosis: Confirm diagnosis through histopathological examination and immunophenotyping of atypical lymphocytes (Evidence: Strong 4).
Supportive Care as First-Line: Prioritize hydration, temperature control, and management of systemic symptoms (Evidence: Moderate 2).
Systemic Corticosteroids for Acute Cases: Use corticosteroids for acute management of erythroderma (Evidence: Moderate 2).
Refer to Specialized Centers: For complex cases, referral to centers with expertise in cutaneous lymphomas is recommended (Evidence: Expert opinion 3).References
1 Akakpo AS, Teclessou JN, Saka B, Mouhari-Toure A, Monsila G, Kombate K et al.. Profile of erythroderma in children in hospital dermatology departments in Lomé, Togo : study of 28 cases. Medecine et sante tropicales 2018. link
2 Sarkar R, Garg VK. Erythroderma in children. Indian journal of dermatology, venereology and leprology 2010. link
3 Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in The Netherlands. Journal of the American Academy of Dermatology 2001. link
4 Judge MR, Shield JP, Cant A, Strobel S, Levin M, Reiser J et al.. Erythroderma, palmoplantar keratoderma and profound failure to thrive in an infant. The British journal of dermatology 1991. link